2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2152 CD3+ T cells from high-risk smoldering multiple myeloma preserve functional competence driving greater teclistamab-mediated cytotoxicity compared to later stages

Anushka Ghosh, PhD, Nayda Bidikian, MD2, Francesco Corrado, MD3, Yoshinobu Konishi, MD, PhD4, Kevin Panaro5, Anna Bosch-Vilaseca6, Casey Gervais7, Rosa Toenges, MD8, Jean-Baptiste Alberge, PhD9, Ting Wu, PhD10, Sophie Magidson, BS11, Lorena Pantano, PhD12, Michelle Aranha, PhD13, David Manuel Cordas Dos Santos, MD14, Shonali Midha, MD15, Elizabeth O'Donnell, MD16, Yuxin Liu, MD17, Ashlee Sturtevant, MSc18, Kenneth Anderson, MD19, Nikhil Munshi, MD20, Jerome Ritz, MD21, Gaddy Getz, PhD22, Omar Nadeem, MD23, Romanos Sklavenitis Pistofidis, MD24, Irene M Ghobrial, MD25
1 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
3 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
4 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
9 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
10 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
13 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
14 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
25 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

INTRODUCTION
Teclistamab (TEC) has demonstrated substantial efficacy in heavily pretreated relapsed/refractory multiple myeloma (RRMM), with emerging evidence of greater efficacy in earlier disease setting including earlier relapse, newly diagnosed multiple myeloma (NDMM), and smoldering multiple myeloma (SMM). This improvement could be attributed to tumor characteristics, preserved T cell functionality, or both. Because TEC mediates T cell engagement with MM cells, we hypothesized that T cells from untreated patients with SMM retain greater proliferative and cytotoxic capacity than those from patients with NDMM and late-stage RRMM. Accordingly, we investigated disease stage–associated differences in T-cell phenotype and function following TEC-mediated activation.

METHODS
Single-cell immune profiling and flow cytometry was used to characterize baseline differences in T-cell composition between patients with HRSMM (n=28) and RRMM (n=30) using an age-adjusted model. CD3+ T cells were isolated from PBMCs collected from patients with NDMM (n=3) and RRMM (n=3) and apheresis cells collected from HRSMM (n=3) and RRMM (n=1) and co-cultured with MM1S cells at an effector to target ratio of 1:1 in the presence (0.1nM) or absence (control) of TEC. In vitro cytotoxicity was measured after 48hrs by flow cytometry and quantified as (1-(% of BCMA+ cells in the presence of TEC/% of BCMA+ cells in control)) *100. T-cell activation was evaluated by CD25 expression, and cytokine production was quantified by ELISA for IL-2 and IFN-γ in the supernatant of the co-culture.

RESULTS
Patients with HRSMM exhibited greater baseline TCR repertoire diversity than those with RRMM (two-sided Wilcoxon, p=0.02). At baseline, patients with RRMM had a higher proportion of cycling and activated CD8? T cells, whereas CD4? naïve and central memory (CM) T cells were significantly depleted compared with HRSMM (q<0.1). Flow cytometric analysis of baseline peripheral blood samples from patients with HRSMM (n=20) and RRMM (n=9) confirmed that patients with HRSMM had higher frequencies of CD4? naïve T cells (medians 21% vs. 7%, q<0.001) and CM T cells (13% vs. 8%, q=0.04) among circulating CD3? T cells. Activated CD8? T cells but not cycling T cells were enriched in patients with RRMM at baseline. This suggests that in patients with HRSMM, the T-cell compartment is relatively less differentiated and preserve proliferative capacity and functional plasticity. However, in patients with RRMM, accumulation of activated/cycling CD8? T cells is associated with terminal differentiation/exhaustion and reflects chronic antigen exposure and progressive immune dysfunction. Patients with HRSMM exhibited a significant increase in T cell clonality and transcriptional signature for T cell activation and cytotoxic effector function post-treatment with TEC compared to those with RRMM that can be attributed to superior endogenous T cell functionality. For functional validation, T cells from HRSMM patients showed greater TEC-mediated killing of MM1S cells than T cells from both NDMM (HRSMM 63.5% vs NDMM 21.9%, one-sided t-test p=0.002) and RRMM patients (HRSMM 63.5% vs RRMM 14%, p<0.001). This enhanced cytotoxicity was associated with increased CD25 expression on HRSMM CD8+ T cells post TEC treatment compared to both patients with NDMM (log2FC: HRSMM 5.24% vs NDMM 3.28%, p=0.02) and RRMM (log2FC: HRSMM 5.24% vs RRMM 2.79%, p=0.01). Enhanced HRSMM T cell response to TEC was further confirmed by detecting higher secretion of IL-2 (HRSMM 447 pg/mL vs RRMM 92.6 pg/mL, p=0.05) and IFN-γ (HRSMM 514 pg/mL vs NDMM 67.1 pg/mL, p=0.04 and HRSMM 5140 pg/mL vs RRMM 0 pg/mL, p=0.03) in the supernatant. Collectively, these findings suggest that the less differentiated state of T cells in HRSMM confers superior TEC–mediated effector function and disease progression results in T-cell remodeling toward a more activated but less functionally competent state.

CONCLUSION
T cells from earlier-stage myeloma, particularly HRSMM, characteristically exhibit greater responsiveness to TEC-directed T-cell activation and cytotoxic effector function than T cells from RRMM. Progressive T cell dysfunction in NDMM and RRMM may contribute to reduced bispecific antibody efficacy, underscoring the therapeutic value of Teclistamab in earlier disease settings as well as highlighting a potential mechanism of treatment resistance in later stages.

Anushka Ghosh, PhD: No relevant conflicts of interest to declare.